Former HHS Secretary Tom Price gets new job as adviser

Four months after resigning as HHS Secretary, Tom Price, MD, has a new gig: serving on the advisory board for Atlanta’s Jackson Healthcare.

The staffing and technology firm made the announcement on Jan. 16, saying Price has “spent his career working to ensure quality care for patients.”

“Nobody has as profound an understanding of the national healthcare landscape as Dr. Price,” Richard Jackson, chairman and CEO of Jackson Healthcare, said in a press release. “Tom has exhibited an unwavering commitment to preserving the patient-physician relationship. That mindset, along with his physician, business and policy experience, will make him an invaluable addition to our board.”

Price resigned from his Cabinet post in September after a POLITICO investigation revealed he racked more than $1 million in publicly-funded travel costs, including taking expensive charter flights when it appeared less expensive commercial travel was available. His 232 days on the job ranks as the shortest tenure of any secretary of HHS.

Since his departure, he has avoided public appearances, though he was reportedly spotted at the JP Morgan Healthcare Conference in San Francisco earlier this month.

The adviser job returns Price to a role in Atlanta’s healthcare system. He practiced in the area beginning in 1984 after completing his residency in orthopedic surgery at Emory University later founding Resurgens Orthopedics. After entering politics as a member of the Georgia Senate, he continued working in medicine as assistant professor at Emory and medical director of Grady Memorial Hospital’s orthopedic clinic.

“I am honored to join the advisory board at Jackson Healthcare,” Price said. “Jackson Healthcare's mission of working to improve patient care is wholly aligned with the work I have done for over four decades, and I look forward to helping them navigate the always changing healthcare environment.”

Price’s fellow board members include ex-politicians like former Florida Gov. and Republican presidential candidate Jeb Bush, as well as healthcare executives like Charles Evans of International Health Services Group and Reynolds Jennings of WellStar Health System.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.